Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) EBT (2023 - 2025)

Historic EBT for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to -$7.6 million.

  • Mangoceuticals' EBT fell 28099.71% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.8 million, marking a year-over-year decrease of 11253.74%. This contributed to the annual value of -$8.7 million for FY2024, which is 548.38% up from last year.
  • Mangoceuticals' EBT amounted to -$7.6 million in Q3 2025, which was down 28099.71% from -$5.4 million recorded in Q2 2025.
  • Mangoceuticals' 5-year EBT high stood at -$1.8 million for Q3 2023, and its period low was -$7.6 million during Q3 2025.
  • For the 3-year period, Mangoceuticals' EBT averaged around -$3.3 million, with its median value being -$2.4 million (2024).
  • Per our database at Business Quant, Mangoceuticals' EBT soared by 2412.15% in 2024 and then plummeted by 28099.71% in 2025.
  • Quarter analysis of 3 years shows Mangoceuticals' EBT stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then crashed by 290.99% to -$7.6 million in 2025.
  • Its EBT was -$7.6 million in Q3 2025, compared to -$5.4 million in Q2 2025 and -$4.8 million in Q1 2025.